See more : Vivendi SE (VVU.DE) Income Statement Analysis – Financial Results
Complete financial analysis of Oncology Pharma Inc. (ONPH) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Oncology Pharma Inc., a leading company in the Biotechnology industry within the Healthcare sector.
You may be interested
- Consolidated Uranium Inc. (CUR.V) Income Statement Analysis – Financial Results
- Vizsla Silver Corp. (0G3.F) Income Statement Analysis – Financial Results
- Tamil Nadu Newsprint and Papers Limited (TNPL.NS) Income Statement Analysis – Financial Results
- Palladium One Mining Inc. (PDM.V) Income Statement Analysis – Financial Results
- Hydraulique P.B Société anonyme (MLHYD.PA) Income Statement Analysis – Financial Results
Oncology Pharma Inc. (ONPH)
About Oncology Pharma Inc.
Oncology Pharma Inc., an oncology company, develops, manufactures, and commercializes therapeutics. The company has a collaboration and licensing agreement with Kalos Therapeutics Inc. for exploring treatment opportunities of the COVID-19 virus. The company was formerly known as SourcingLink.net Inc. and changed its name to Oncology Pharma Inc. in June 2019. Oncology Pharma Inc. was incorporated in 1993 and is based in San Francisco, California.
| Metric | 2022 | 2021 | 2020 | 2019 | 2018 | 2004 | 2003 | 2002 | 2001 | 2000 | 1999 | 1998 | 1997 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 1.18M | 3.28M | 3.67M | 4.01M | 993.40K | 892.19K | 1.27M | 1.03M |
| Cost of Revenue | 0.00 | 0.00 | 779.00 | 1.11K | 1.11K | 654.00K | 1.21M | 1.36M | 1.34M | 321.60K | 624.82K | 837.13K | 554.03K |
| Gross Profit | 0.00 | 0.00 | -779.00 | -1.11K | -1.11K | 527.00K | 2.07M | 2.31M | 2.68M | 671.80K | 267.38K | 437.48K | 477.82K |
| Gross Profit Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 44.62% | 63.05% | 63.02% | 66.68% | 67.63% | 29.97% | 34.32% | 46.31% |
| Research & Development | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 376.00K | 780.00K | 773.00K | 954.18K | 1.18M | 407.48K | 364.54K | 0.00 |
| General & Administrative | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Selling & Marketing | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A | 0.00 | 62.05K | 14.41M | 402.77K | 817.76K | 1.85M | 2.91M | 3.56M | 3.08M | 3.83M | 2.34M | 2.91M | 3.20M |
| Other Expenses | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Operating Expenses | 0.00 | 62.05K | 14.41M | 402.77K | 817.76K | 2.23M | 3.69M | 4.33M | 4.24M | 5.42M | 2.75M | 3.28M | 3.23M |
| Cost & Expenses | 0.00 | 62.05K | 14.41M | 403.88K | 818.86K | 2.88M | 4.91M | 5.69M | 5.57M | 5.74M | 3.38M | 4.11M | 3.78M |
| Interest Income | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 5.00K | 0.00 | 86.00K | 243.24K | 242.81K | 0.00 | 98.24K | 0.00 |
| Interest Expense | 0.00 | 104.62M | 82.81M | 25.00K | 31.53K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Depreciation & Amortization | 228.49K | 236.56K | 779.00 | 1.11K | 1.11K | 81.00K | 395.00K | 341.00K | 457.28K | 402.82K | 63.54K | 79.91K | 21.79K |
| EBITDA | 0.00 | -7.88K | -14.66M | -181.45K | -817.76K | -1.75M | -1.48M | -1.13M | -1.61M | -1.08M | -4.33M | -2.02M | -2.38M |
| EBITDA Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | -148.26% | -40.09% | -45.04% | -27.00% | -435.57% | -266.43% | -213.65% | -263.15% |
| Operating Income | 0.00 | -62.05K | -14.41M | -403.88K | -818.86K | -1.70M | -1.63M | -2.02M | -1.82M | -4.75M | -2.49M | -2.84M | -2.75M |
| Operating Income Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | -144.03% | -49.54% | -54.90% | -45.26% | -477.69% | -278.54% | -222.78% | -266.35% |
| Total Other Income/Expenses | 0.00 | -104.56M | -83.06M | 196.33K | -31.53K | 131.00K | 136.00K | 105.00K | -135.39K | 222.15K | 227.17K | 720.08K | -274.44K |
| Income Before Tax | 0.00 | -104.63M | -97.47M | -207.56K | -850.40K | -1.57M | -1.54M | -2.04M | -1.59M | -4.76M | -2.53M | -2.88M | -2.76M |
| Income Before Tax Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | -132.94% | -46.95% | -55.47% | -39.72% | -479.26% | -283.52% | -225.64% | -267.43% |
| Income Tax Expense | 0.00 | -236.56K | 3.49K | 1.00 | 1.00 | -136.00K | -105.00K | -65.00K | 31.75K | -227.17K | 25.73K | -61.78K | -36.67K |
| Net Income | 0.00 | -104.63M | -97.47M | -207.56K | -850.40K | -1.57M | -1.52M | -1.95M | -1.59M | -4.52M | -2.51M | -2.78M | -2.71M |
| Net Income Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | -132.51% | -46.34% | -53.13% | -39.72% | -454.82% | -281.42% | -217.93% | -262.79% |
| EPS | 0.00 | -3.42 | -6.76 | -0.12 | -0.72 | -782.50K | -1.52M | -1.95M | -1.59M | -4.52M | 0.00 | 0.00 | 0.00 |
| EPS Diluted | 0.00 | -3.42 | -6.76 | -0.12 | -0.72 | -782.50K | -1.52M | -1.95M | -1.59M | -4.52M | 0.00 | 0.00 | 0.00 |
| Weighted Avg Shares Out | 38.56M | 30.55M | 14.42M | 1.68M | 1.19M | 2.00 | 1.00 | 1.00 | 1.00 | 1.00 | 0.00 | 0.00 | 0.00 |
| Weighted Avg Shares Out (Dil) | 38.56M | 30.55M | 14.42M | 1.68M | 1.19M | 2.00 | 1.00 | 1.00 | 1.00 | 1.00 | 0.00 | 0.00 | 0.00 |
Oncology Pharma, Inc. Has Engaged a PCAOB Audit Firm Looking Towards Moving the Company Towards a Senior Listing
SAN FRANCISCO, CA / ACCESSWIRE / October 15, 2021 / Oncology Pharma Inc. (OTC PINK:ONPH) Pursuant to previously announced press release, Oncology Pharma, Inc. (the "Company") has retained the services of DBBMcKennon, LLC, a PCAOB Certified Public Accounting Firm. The...
Oncology Pharma, Inc. Has Received the Committed Funding to Perform All Necessary IND-Enabling Preclinical Work for Its First Lead Candidate, a Dactinomycin Nanoemulsion Drug Product
SAN FRANCISCO, CA / ACCESSWIRE / September 13, 2021 / Oncology Pharma, Inc. (OTC PINK:ONPH). In keeping with management's commitment to continue implementation of Oncology Pharma's ("the Company") capital formation plan, the Company has obtained, received and segregated all funds...
Oncology Pharma's Co-Development Agreement Pursues Strategic and Direct Objectives
SAN FRANCISCO, CA / ACCESSWIRE / August 23, 2021 / Oncology Pharma, Inc. (OTC PINK:ONPH) defines its objective and strategy for recently signed Co-Development deal. The primary goal of the Co-Development plan is to bring new pharmaceutical drug formulations to...
Oncology Pharma, Inc. Executes Co-Development Agreement with NanoSmart Pharmaceuticals, Inc.
SAN FRANCISCO, CA / ACCESSWIRE / August 19, 2021 / Oncology Pharma Inc. (OTC PINK:ONPH) With much anticipation, Oncology Pharma, Inc. has finalized a Co-Development Agreement with NanoSmart Pharmaceuticals, Inc. Oncology Pharma will pursue the early feasibility and nonclinical development...
Oncology Pharma, Inc. To Move to Conducting Trials on Licensed IP
SAN FRANCISCO, CA / ACCESSWIRE / July 20, 2021 / Oncology Pharma Inc. (OTC PINK:ONPH) Oncology Pharma, Inc. (the "Company") is laying out and taking necessary steps to move its licensed IP forward. From obtaining the necessary financing, in order...
Oncology Pharma, Inc. is Entering Into the Next Phase of its Growth and Expansion Phase
SAN FRANCISCO, CA / ACCESSWIRE / June 30, 2021 / Oncology Pharma Inc. (OTC PINK:ONPH) Oncology Pharma, Inc. (the "Company") is developing a program to establish the use of its license utilizing NR2F6 agonists and antagonists coupled with the proprietary...
Shares of This Biotech Stock Could Jump 437%
Published by: Tim Kraimer Oncology Pharma, Inc. (Symbol: ONPH) is a San Francisco-based biotech company that has been making one blockbuster announcement after the next. These announcements have sent the stock soaring from $0.40 to over $30 and it's still...
Oncology Pharma, Inc. Is Pursuing the Development of Its Small Molecule Drug for the Treatment of Colon Cancer
SAN FRANCISCO, CA / ACCESSWIRE / May 18, 2021 / Oncology Pharma Inc. (OTC PINK:ONPH) Oncology Pharma, Inc. (the "Company") is pursuing, through its licensing arrangements, the development of a small molecule drug ("SMD") for the treatment of colon cancer....
This Biotech Stock Could Jump +500%
Published by: Nick Martin Oncology Pharma, Inc. (Symbol: ONPH) is a San Francisco-based biotech company that has been making one blockbuster announcement after the next. These announcements have sent the stock up from $0,50 to over $30 this year...
Oncology Pharma, Inc. Has Submitted Its Initial Application to List the Company on the Capital Markets Tier of the NASDAQ Exchange
SAN FRANCISCO, CA / ACCESSWIRE / May 12, 2021 / Oncology Pharma Inc. (OTC PINK:ONPH) Oncology Pharma, Inc. (the "Company") has submitted its initial application to the NASDAQ to begin the process of moving the listing from the Pink Sheets to...
Source: https://incomestatements.info
Category: Stock Reports